---

title: 'Post-Exposure Prophylaxis, non-occupational contact'
authors:
    - 'Michelle Lin, MD'
created: 2011/04/01
updates: null
categories:
    - 'Infectious Disease'
drugs: null

---



# Post-Exposure Prophylaxis (PEP): Non-Occupational Contact

**National Clinicians’ Post-Exposure Prophylaxis Hotline of the National HIV/AIDS Clinicians’ Consultation Center**

-   **Phone:** [1-888-448-4911](tel:8884484911%20) (24 hrs/day)
-   To consult on occupational AND non-occupational exposure to HIV

## Baseline Testing of Exposed Patient

-   HIV
-   Hepatitis B (specifically HBsAb for immunity) 
-   Hepatitis C antibody 
-   Gonorrhea
-   Chlamydia 
-   Syphilis
-   CBC
-   Creatinine
-   LFT
-   Pregnancy, if appropriate 

## Risk of HIV

-   Receptive anal intercourse: 1-30% risk
-   Insertive anal or receptive vaginal intercourse: 0.1-10% risk
-   Oral intercourse: “very low risk” but not zero risk
-   Needle sharing with injection drug use: 0.67% per needle-sharing contact 

## High-Risk Source Patient

-   Known HIV+ source patient 
-   High-risk populations
-   Men who have sex with men+/-women
-   Commercial sex workers
-   Injection drug users
-   History of incarceration
-   From a country with HIV seroprevalence ≥ 1%
-   Persons with sexual partner in this high-risk population group 

## If Decide to Give PEP for Possible HIV Exposure

-   **Timing:** The sooner the treatment, the better. Starting treatment ≤ 48 hours after exposure is best. Still eligible if present ≤ 72 hours per CDC.
-   **Effectiveness:** PEP is associated with 81% decrease in HIV transmission.
-   **Duration of treatment** = 28 days

**TREATMENT OPTIONS:**

Option \#1: **Combivir** (300 mg <span class="drug">zidovudine</span>-150 mg <span class="drug">lamivudine</span>)- 1 tab po BID

  - Side Effects:
  - Nausea
  - Anemia
  - Hepatotoxic
  - Neutropenia
  - Asthenia

Option \#2: **Truvada** (300 mg <span class="drug">tenofovir</span>-200 mg <span class="drug">emtricitabine</span>) – 1 tab po Qday (Side effects: Nephrotoxic)
For very high-risk exposure: Can add to Option \#1 or \#2:
-   **Kaletra (<span class="drug">ritonavir</span>-<span class="drug">lopinavir</span>)** (Side effects: Hepatotoxic, diarrhea), or
-   **<span class="drug">Ritonavir</span>** plus **<span class="drug">Atazanavir</span>** 

  - Side Effects:
  - Hepatotoxic
  - jaundice
  - renal stones

-   **<span class="drug">Ritonavir</span>** plus **<span class="drug">Darunavir</span>** (Side effects: Hepatotoxic, diarrhea)

**Followup HIV and syphilis test at 4-6 weeks, 3 months, 6 months post-exposure**

## Additional Treatment

[CDC Sexual Assault and STD website](http://www.cdc.gov/std/treatment/2010/sexual-assault.htm)

-   **<span class="drug">Ceftriaxone</span>** 250 mg IM x 1 (for Gonorrhea) - or can give IV
-   **<span class="drug">Azithromycin</span>** 1 g po x 1 (for Chlamydia)
-   **<span class="drug">Metronidazole</span>** 2 g po x 1 (for trichomonas)
-   Consider **emergency contraception** for women
-   **Hep B vaccination**, if not fully vaccinated – need to finish series at 1-2 & 4-6 mo 

## References

-   [Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29;361(18):1768-75.](http://www.ncbi.nlm.nih.gov/pubmed/?term=19864675)
